Incyte plant Kooperation mit Bristol Myers Squibb zur Behandlung von Bauchspeicheldrüsenkrebs

• Incyte plant zwei klinische Kooperationen mit Bristol Myers Squibb und Synnovation zur Entwicklung von Kombinationstherapien gegen fortgeschrittenen oder metastasierten Bauchspeicheldrüsenkrebs.
• Geplante Phase-1b-Studien sollen den KRAS-G12D-Hemmer INCB161734 jeweils mit Navlimetostat von Bristol Myers Squibb oder SNV1521 von Synnovation prüfen.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202610260945BIZWIRE_USPR_____20261026_BW987057) on October 26, 2026, and is solely responsible for the information contained therein.